Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations

Haznedaroglu I. C.

EXPERT OPINION ON PHARMACOTHERAPY, cilt.14, sa.15, ss.2005-2010, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 14 Sayı: 15
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1517/14656566.2013.833185
  • Dergi Adı: EXPERT OPINION ON PHARMACOTHERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2005-2010
  • Hacettepe Üniversitesi Adresli: Hayır

Özet

Introduction: The aim of this paper is to indicate optimal tyrosine kinase inhibitor (TKI) administration practices based on European LeukemiaNet (ELN) 2013 recommendations for chronic myeloid leukemia (CML). Likewise, current concerns of undertreatment and overtreatment with TKIs during the long-term clinical course of CML will be outlined.